Indivior Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Indivior kazanç ve gelirin sırasıyla yıllık 49.4% ve 5.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 46.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 203.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

49.4%

Kazanç büyüme oranı

46.7%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	18.4%
Gelir büyüme oranı	5.5%
Gelecekteki özkaynak getirisi	203.4%
Analist kapsamı	Good
Son güncelleme	25 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Positive Sentiment Still Eludes Indivior PLC (LON:INDV) Following 26% Share Price Slump

Sep 24

Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story

Aug 09

Indivior PLC's (LON:INDV) Shares Not Telling The Full Story

May 29

Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why

May 03

Kazanç ve Gelir Büyüme Tahminleri

LSE:INDV - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,210	317	272	311	5
12/31/2025	1,101	189	145	209	7
12/31/2024	1,157	75	120	16	7
9/30/2024	1,182	-3	-273	-240	N/A
6/30/2024	1,147	-141	-279	-227	N/A
3/31/2024	1,124	5	-383	-334	N/A
12/31/2023	1,093	2	-368	-315	N/A
9/30/2023	1,042	-235	-89	-52	N/A
6/30/2023	1,002	-59	-22	-11	N/A
3/31/2023	947	-50	23	35	N/A
12/31/2022	901	-53	-9	-4	N/A
9/30/2022	882	166	176	181	N/A
6/30/2022	838	152	160	145	N/A
3/31/2022	818	166	175	189	N/A
12/31/2021	791	205	339	353	N/A
9/30/2021	753	156	101	115	N/A
6/30/2021	725	139	81	115	N/A
3/31/2021	674	95	39	42	N/A
12/31/2020	647	-148	-197	-193	N/A
9/30/2020	595	-190	-84	-82	N/A
6/30/2020	634	-152	-70	-69	N/A
3/31/2020	700	-95	-131	-130	N/A
12/31/2019	785	134	148	151	N/A
9/30/2019	889	213	217	200	N/A
6/30/2019	935	254	281	275	N/A
3/31/2019	988	248	401	413	N/A
12/31/2018	1,005	275	299	303	N/A
9/30/2018	1,033	106	247	276	N/A
6/30/2018	1,064	67	N/A	210	N/A
3/31/2018	1,083	71	N/A	260	N/A
12/31/2017	1,093	58	N/A	295	N/A
9/30/2017	1,087	281	N/A	360	N/A
6/30/2017	1,080	81	N/A	409	N/A
3/31/2017	1,065	65	N/A	370	N/A
12/31/2016	1,058	35	N/A	407	N/A
9/30/2016	1,047	-6	N/A	326	N/A
6/30/2016	1,028	191	N/A	283	N/A
3/31/2016	1,021	201	N/A	252	N/A
12/31/2015	1,014	228	N/A	320	N/A
9/30/2015	1,037	268	N/A	300	N/A
6/30/2015	1,058	314	N/A	369	N/A
3/31/2015	1,085	361	N/A	530	N/A
12/31/2014	1,115	403	N/A	440	N/A
9/30/2014	1,147	443	N/A	572	N/A
12/31/2013	1,216	489	N/A	791	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: INDV önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.1% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: INDV önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: INDV önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: INDV şirketinin gelirinin (yıllık 5.5% ) UK pazarından (yıllık 3.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: INDV şirketinin gelirinin (yıllık 5.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: INDV 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 203.4 %).

Indivior Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Consensus EPS estimates increase by 44%

Consensus EPS estimates fall by 37%

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024

Indivior plc Reaffirms Revenue Guidance for the Year 2024

Recent updates

Oaktree Capital Sends a Letter to Indivior PLC

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Indivior PLC's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board

Positive Sentiment Still Eludes Indivior PLC (LON:INDV) Following 26% Share Price Slump

Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use Disorder

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story

Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain Officers

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million.

Consensus EPS estimates increase by 44%

Consensus EPS estimates fall by 37%

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024

Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression

Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder

Indivior PLC's (LON:INDV) Shares Not Telling The Full Story

Indivior plc Reaffirms Revenue Guidance for the Year 2024

Indivior PLC Announces Board Committee Changes

Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why

Indivior plc Reconfirms Earnings Guidance for 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024

CEO & Executive Director recently sold UK£1.5m worth of stock

Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

Chief Human Resources Officer recently sold UK£1.8m worth of stock

The Market Lifts Indivior PLC (LON:INDV) Shares 26% But It Can Do More

Full year 2023 earnings released: EPS: US$0.015 (vs US$0.38 loss in FY 2022)

Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024

Are Investors Undervaluing Indivior PLC (LON:INDV) By 50%?

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million.

Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023

New major risk - Financial position

Third quarter 2023 earnings released: US$0.98 loss per share (vs US$0.29 profit in 3Q 2022)

Indivior PLC Announces Executive Changes

Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC to Report Q3, 2023 Results on Nov 09, 2023

Two Seas Capital Provides Information to Shareholders of Indivior PLC

Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023

Indivior PLC Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.28 (vs US$0.34 in 2Q 2022)

Indivior PLC to Report Q2, 2023 Results on Jul 27, 2023

Indivior PLC to Report First Half, 2023 Results on Jul 27, 2023

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

Chief Manufacturing & Supply Officer recently sold UK£1.7m worth of stock

Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS misses analyst expectations

Full year 2022 earnings: Revenues in line with analyst expectations

Indivior PLC Announces Board and Committee Changes

Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023

Indivior PLC Reiterates Earnings Guidance for the Fiscal Year 2022

Here's Why Indivior (LON:INDV) Can Manage Its Debt Responsibly

High number of new directors

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Third quarter 2022 earnings released: EPS: US$0.29 (vs US$0.18 in 3Q 2021)

Aquestive Therapeutics Announces Positive Decision in States' Suboxone Antitrust Lawsuit on All Claims

Indivior PLC to Report Q3, 2022 Results on Oct 27, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S

Indivior PLC Provides Revenue Guidance for the Full Year